We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Maternal HbA1c Influences Autism Risk in Offspring

By LabMedica International staff writers
Posted on 04 Jul 2019
Epidemiologic data suggest that maternal diabetes influences the risk for autism in offspring, whereas the prevalence of autism has steadily risen in the USA, currently affecting 1 in 59 children, and boys are four to five times more likely to receive an autism diagnosis.

According to a comprehensive survey children born to women with glycated hemoglobin (HbA1c) level of at least 6.5% were nearly twice as likely to receive a diagnosis of autism in the first four years of life versus offspring of mothers with HbA1c below 5.7%.

Scientists carried out a retrospective study and analyzed electronic medical records data from 35,819 mother-infant pairs (51% boys) born in hospitals connected to Kaiser Permanente Southern California (Pasadena, CA, USA) from 2012 to 2013 (maternal mean maternal age, 31 years; mean pre-pregnancy BMI, 27.2 kg/m²; 51% Hispanic). More...
The team followed the children until they received a diagnosis of autism with at least one diagnostic code or December 31, 2017. The last maternal HbA1c level in the first two trimesters of pregnancy was obtained from the electronic laboratory database. HbA1c was analyzed as a continuous variable and a categorical variable, classified as less than 5.7%, 5.7% to 5.9%, 6% to 6.5%, and greater than 6.5%.

Within the cohort, 84.9% of mothers had an HbA1c less than 5.7%; 11.7% had an HbA1c between 5.7% and 5.9; 2.4% between 6% and 6.5%; and 1% greater than 6.5%. During a median follow-up of 4.5 years, 707 children (2%) had a clinical diagnosis of autism. After adjusting for pre-pregnancy BMI and race, the Hazard Ratio (HR) for autism associated with each 1% increase of HbA1c level was 1.12 (95% CI, 0.96-1.31) for the continuous measure. Compared with children with a maternal HbA1c of less than 5.7%, children born to women with an HbA1c greater than 6.5% were nearly twice as likely to receive a diagnosis of autism during follow-up (HR = 1.79; 95% CI, 1.06-3).

Anny H. Xiang, PhD, director of biostatistics for Kaiser Permanente Southern California, said, “Maternal diabetes, if not well treated, which means hyperglycemia in utero, that increases uterine inflammation, oxidative stress and hypoxia and may alter gene expression. This can disrupt fetal brain development, increasing the risk for neural behavior disorders, such as autism.” The study was presented at the American Diabetes Association 79th Scientific Meeting held June 7-11, 2019, in San Francisco, CA, USA.

Related Links:
Kaiser Permanente Southern California


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.